FrankASinicropeMDFACP
Gastroenterology • Rochester, MNGastrointestinal Cancer, Hepatology & Liver Transplantation
Professor, Internal Medicine and Oncology, Mayo Medical School
Dr. Sinicrope is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
200 1st Street SW
Rochester, MN 55905- Is this information wrong?
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1996 - 1997
University of ChicagoFellowship, Gastroenterology, 1989 - 1992
Michael Reese Hospital and Medical CenterResidency, Internal Medicine, 1986 - 1988
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1985
Certifications & Licensure
CA State Medical License 1991 - Present
MN State Medical License 2002 - 2024
TX State Medical License 1992 - 2003
IL State Medical License 1985 - 1993- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Gastroenterology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer Start of enrollment: 2004 Feb 01
- Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum Start of enrollment: 2004 Dec 01
- Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer Start of enrollment: 2009 Aug 20
- Join now to see all
Publications & Presentations
PubMed
- Ferroptosis: Biology and Role in Gastrointestinal Disease.Juan-José Escuder-Rodríguez, Deguang Liang, Xuejun Jiang, Frank A Sinicrope> ;Gastroenterology. 2024 Mar 1
- Metastatic site and clinical outcome of patients with deficient mismatch repair metastatic colorectal cancer treated with an immune checkpoint inhibitor in the first-l...Bahar Saberzadeh-Ardestani, Jeremy C Jones, Robert R McWilliams, David Tougeron, Thorvardur R Halfdanarson, Rosine Guimbaud, Joleen M Hubbard, Qian Shi, Emily Alouani,...> ;European Journal of Cancer. 2024 Jan 1
- 1 citationsTranscriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors.Claire Gallois, Matteo Landi, Julien Taieb, Marine Sroussi, Bahar Saberzadeh-Ardestani, Antoine Cazelles, Sara Lonardi, Francesca Bergamo, Rossana Intini, Giulia Madda...> ;Clinical Cancer Research. 2023 Sep 15
- Join now to see all
Journal Articles
- MiR-139-5p as a Novel Serum Biomarker for Recurrence and Metastasis in Colorectal CancerFrank A Sinicrope, Steven R Alberts, Ajay Goel, Nature
Lectures
- Relative contribution of clinical and molecular features to outcome within low and high risk T and N groups in stage III colon cancer (CC).2019 ASCO Annual Meeting - 6/1/2019
- Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repai...2019 ASCO Annual Meeting - 6/1/2019
- Validation of tumor infiltrating lymphocytes (TIL) and tumor budding as predictors of prognosis in patients with stage III colon cancers treated in a FOLFOX-based adju...2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
- Join now to see all
Press Mentions
Mayo Clinic Expert Calls for Public Health Measures to Improve Diet, Reduce Cancer RiskApril 27th, 2022- Tumor Cell PD-L1 May Mediate Sensitivity to Chemotherapy in Colorectal Cancer TreatmentJuly 2nd, 2021
WVU Health System to Manage 203-Bed HospitalDecember 18th, 2020- Join now to see all
Grant Support
- Translational Research In Colon Cancer Prevention &TreatmentNational Cancer Institute2009–2011
- Polyphenon E For The Chemoprevention Of Colorectal CancerNational Cancer Institute2008–2011
- Aberrant Crypt FOCI As A Biomarker For ChemopreventionNational Cancer Institute2006–2009
- Clinical Significance Of Apoptosis In Colon CancerNational Cancer Institute2004–2006
- Clinical Significance Of Apoptosis In Colon CancerNational Cancer Institute2003
- Beta-Catenin And RAR Interact At The PKC Alpha PromoterNational Institute Of Diabetes And Digestive And Kidney Diseases2002
- A Three Arm Phase II Chemoprevention Trial In AdenomatouDivision Of Cancer Prevention And Control1999–2000
- Calcium And Aspirin Prevention TrialNational Cancer Institute1997
Professional Memberships
- Member
Hospital Affiliations
Mayo Clinic Hospital - RochesterRochester, Minnesota
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
